Singapore's first flu vaccine demonstrates positive Phase I results
The clinical trial of gH1-Qbeta demonstrated an induced immune response with good cross-reactivity to recently drifted H1N1 strains. The vaccine was also safe and well tolerated with no adverse events reported during the trial.
A*STAR is developing the vaccine under a collaborative research, development and commercialization agreement with Cytos. The vaccine candidate is based on Cytos' proprietary bacteriophage Qbeta virus-like particle technology.
"We are very pleased with the outcome of this trial," Alex Matter, the CEO of A*STAR's Experimental Therapeutics Center, said. "The favorable data demonstrates that the VLP-vaccine strategy is an effective one. We are now planning, in conjunction with Cytos, the next steps for this project."
Under the terms of the agreement, Cytos retains the worldwide right to develop and commercialize gH1-Qbeta globally, while A*STAR subsidiaries retain the right to develop and commercialize the vaccine for Singapore and other countries in the Association of Southeast Asian Nations.
"We are encouraged to see seroconversion in patients treated with our bacterially derived recombinant flu vaccine and are evaluating next steps with our partner A*STAR," Christian Itin, the chairman and CEO of Cytos, said. "The results of this study further support the utility of our VLP vaccine platform for the treatment of infectious diseases."
Cytos is a public biopharmaceutical company focused on developing targeted immunotherapies.
A*STAR is Singapore's lead public sector agency. It is meant to foster world-class scientific research and talent in order to transform Singapore's economy.